NDAORALCAPSULEPriority Review
Approved
May 2020
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
6/8 — Strong
Priority Review
RETEVMO (selpercatinib) by Eli Lilly and Company is rearranged during transfection (ret) inhibitors [moa]. Approved for kinase inhibitor [epc]. First approved in 2020.
Drug data last refreshed 14h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RETEVMO (selpercatinib) is an oral, small-molecule RET kinase inhibitor approved in May 2020 for RET-driven cancers including medullary thyroid carcinoma and RET-fusion positive non-small cell lung cancer. It selectively blocks the Rearranged during Transfection (RET) protein, which drives oncogenic signaling in patients with specific genetic mutations.
$58MPart D
Growth12.5 years to LOEEarly-stage commercial trajectory with modest Part D spend of $58M (2023) suggests an emerging franchise with room for market expansion and growing team investment.
Mechanism of Action
Rearranged during Transfection (RET) Inhibitors
Pharmacologic Class:
Kinase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Study of Selpercatinib (LY3527723) in Participants With Rearranged During Transfection (RET)-Altered Cancers in India
Started Nov 2026
30 enrolled
Thyroid NeoplasmsCarcinoma, Non-Small-Cell Lung
Selpercatinib Pre-RAI in Patients With RET Fusion Thyroid Cancer (RAISE)
Started Jul 2024
13 enrolled
Differentiated Thyroid CancerPediatric CancerCancer+1 more
A Drug Drug Interaction (DDI) Study of Selpercatinib (LY3527723) and Rosuvastatin in Healthy Participants
Started Jul 2023
28 enrolled
Healthy
Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC
Started Mar 2023
30 enrolled
Thyroid CancerThyroid CarcinomaMetastatic Thyroid Cancer+3 more
A Study of the Effect of Food on Selpercatinib (LY3527723) in Healthy Participants
Started Apr 2022
46 enrolled
Healthy
Worked on RETEVMO at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.